High-dose melphalan followed by autologous stem cell transplantation remains the standard of care for eligible patients with multiple myeloma, but disease response and toxicity, including severe mucositis, varies among patients. Our randomized trial investigated duration of cryotherapy (2 and 6 h) for reduction of mucositis prevalence and severity and explored factors associated with variability in pharmacokinetics and outcomes from melphalan therapy. The results demonstrate that 2-h is at least as effective as 6-h cryotherapy in decreasing severe mucositis. From a population pharmacokinetic model, we identified that fat-free mass, hematocrit, and creatinine clearance were significant covariates, as reported previously. Furthermore, we observed the rs4240803 SLC7A5 polymorphism was significantly associated with pharmacokinetic variability, and pharmacokinetics was associated with both mucositis and neutropenia. However, melphalan exposure was not associated with progression-free or overall survival in our dataset. These findings contribute to ongoing efforts to personalize melphalan dosing in transplant patients.
High-dose melphalan followed by autologous stem cell transplantation remains the standard of care for eligible patients with multiple myeloma, but disease response and toxicity, including severe mucositis, varies among patients. Our randomized trial investigated duration of cryotherapy (2 and 6 h) for reduction of mucositis prevalence and severity and explored factors associated with variability in pharmacokinetics and outcomes from melphalan therapy. The results demonstrate that 2-h is at least as effective as 6-h cryotherapy in decreasing severe mucositis. From a population pharmacokinetic model, we identified that fat-free mass, hematocrit, and creatinine clearance were significant covariates, as reported previously. Furthermore, we observed the rs4240803 SLC7A5 polymorphism was significantly associated with pharmacokinetic variability, and pharmacokinetics was associated with both mucositis and neutropenia. However, melphalan exposure was not associated with progression-free or overall survival in our dataset. These findings contribute to ongoing efforts to personalize melphalan dosing in transplant patients.
Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
þ Current practice utilizes fixed doses of high-dose melphalan for HSCT conditioning, but the factors underlying the high variability in patient outcomes, including adverse effects, remain unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This randomized trial aimed to identify an efficacious and tolerable cryotherapy regimen. Additionally, correlative analyses aimed to identify pharmacokinetic/pharmacodynamic factors that account for interpatient variability with respect to patient outcomes. WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ We show that 2 h of cryotherapy is equally effective as 6 h. Population pharmacokinetic modeling and investigation of pharmacodynamic endpoints verified fat-free mass, hematocrit, and creatinine clearance as significant covariates; furthermore, the SLC7A5 genotype was identified as a significant covariate and improved model fitting.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE
þ This study provides randomized clinical trial results supporting a shorter and well-tolerated cryotherapy regimen that is at least as efficacious as the standard. Combining the presented data and pharmacokinetic model with other significant covariates that influence patient outcomes could lead to construction of a dosing algorithm that optimizes patient safety and clinical response.
Autologous hematopoietic stem cell transplant (HSCT) for patients with multiple myeloma (MM) is currently the standard of care and highly effective, with $5,000 transplants performed annually in the United States. [1] [2] [3] [4] Melphalan, an interstrand DNA cross-linking agent, remains the standard chemotherapy regimen for HSCT in MM, and patients are treated with either 140 mg/m 2 or 200 mg/m 2 depending on the presence or absence of significant medical comorbidities. 5 Treatment with high-dose melphalan (HDM) is associated with variable durations and severities of oral mucositis, enteritis, and neutropenia.
Severe oral mucositis following HDM is a primary source of patient discomfort and is associated with several unfavorable outcomes, including longer duration of febrile neutropenia, doubling of infectious risk, two to three additional days of total parenteral nutrition (TPN) use, intravenous narcotic use, longer length of hospital stay, and a 3.9-fold increase in 100-day mortality; factors leading to an increase of $25,405 (US) in hospital charges. 6 Numerous strategies to decrease the incidence of mucositis have been employed, including routine oral care, saline rinses, palifermin, and artificial saliva (Caphosol). However, the use of oral cryotherapy remains superior. [7] [8] [9] [10] [11] It has been previously shown that 6 h of oral cryotherapy significantly reduces mucositis, 8 although patients often find this duration to be quite uncomfortable, and many do not adhere to the cryotherapy regimen during the full 6 h. While the minimal necessary duration of cryotherapy required to reduce the incidence of severe mucositis has not been identified, other studies suggest that shorter durations including 1 h 10 and less than 2 h 12 result in tolerability and outcomes that may be comparable to 6 h. Despite these reports, no prospective randomized trial has been completed that confirms cryotherapy duration shorter than 6 h leads to similar patient outcomes, reduced length of hospitalization, and decreased incidence of bacteremia. 8, 10, 11 Despite improvements in supportive care, many HSCT patients continue to experience significant toxicities following HDM. It is presently unclear why certain patients tolerate treatment better than others, although interpatient variability in melphalan pharmacokinetics and inherent sensitivity to the cytotoxic effects of melphalan are suspected to be important factors. Pharmacokinetic (PK) analysis has identified pretreatment hematocrit, fat-free mass, and estimated creatinine clearance as significant sources of interpatient variability. 13 Additionally, pharmacodynamic (PD) characteristics, such as induction of ex vivo apoptosis, modulation of p53 expression in peripheral blood mononuclear cells (PBMCs), and the ability to repair double-strand breaks in primary myeloma cells have been identified as factors associated with response and toxicity. 14, 15 Similarly, a single nucleotide polymorphism (rs4240803) in SLC7A5, a gene that encodes L-type amino acid transporter 1 (LAT1), which is a transporter that mediates melphalan uptake into cells, 16, 17 has been associated with TPN requirement following development of HDM-related gastrointestinal toxicity. 18 Collectively, these findings suggest that intrinsic PK and PD variables can be used to better understand and potentially predict the in vivo activity and an individual's sensitivity to melphalan.
To investigate whether a shorter duration of cryotherapy would be at least as effective as a standard 6-h regimen for minimization of severe oral mucositis (grade 3 or higher), our group performed a prospective randomized noninferiority trial investigating 2 vs. 6 h of cryotherapy in 146 patients with MM. Additionally, we collected patient samples to further explore sources of interpatient variability in melphalan PK and outcomes from therapy. Our results establish 2 h of cryotherapy as the new standard of care for mucositis prophylaxis, and we have further explored within this cohort of patients factors that explain portions of melphalan interpatient PK variability and associations of PK with clinical outcomes.
RESULTS Patients
A total of 146 patients consecutively admitted for HSCT were consented, registered, and randomized to receive either 2-or 6-h of cryotherapy ( Table 1) . Each treatment arm included 73 patients, with all patients receiving treatment as randomized. Overall, the median age was 59 (range 35-72), 62% (90/146) were male, and 87% (127/146) were White, 61% (89/146) had Table 2 ). These differences were well within the 15% noninferiority margin set during the design stage. Additionally, in patients who experienced mucositis of any grade, the onset of worst grade symptoms was not significantly different between patients treated in the 2-h cohort (mean (SD): 9.4 days (3.0)) and those in the 6-h cohort (8.5 days (3.6), difference: 0.85 days, 95% CI: -0.53, 2.24) (Supplementary Figure 1 ). There were also no significant differences in the incidence of bacteremia or length of hospitalization between randomized groups ( Table 2) . Forty-five patients had bacteremia that occurred on a median of 7 days posttransplant in both groups (27.4% of patients in the 2-h cohort (n 5 20) and 34.2% of patients in the 6-h cohort (n 5 25), risk difference: 6.8%, 95% CI: -21.8%, 8.1%). Patient length of hospitalization was on average 14.8 days (14.7 (2.9) vs. 14.9 (2.8) days in the 2-and 6-h cohorts, respectively, difference: 0.29 days, 95% CI: -1.22, 0.65). Adjusted for age and randomized group, the incidence of bacteremia or the length of hospital stay was not strongly associated with grade of mucositis (adjusted incidence of bacteremia: 36.0% (mucositis grade 2-3) vs. 29.8% (mucositis grade 0-1), difference 7.6%, 95% CI: -13.5, 28.7; Adjusted length of stay: 15.8 days (mucositis grade 2-3) vs. 14.6 days (mucositis grade 0-1), difference 0.90 days, 95% CI: -0.33, 2.14).
SLC7A5 genotyping
Genomic DNA extracted from pretransplant baseline PBMCs was available from 105 patients and was used to determine SLC7A5 rs4240803 genotype. The SLC7A5 rs4240803 homozygous minor allele genotype (AA) was observed in nine patients, the heterozygous allele (AG) in 46 patients, and homozygous major allele (GG) in 50 patients (Table 1) . Overall, the genotype distribution of SLC7A5 rs4240803 in this cohort of patients follows Hardy-Weinberg equilibrium. The minor allele frequency (MAF) obtained in this study, 30.7%, is comparable to the reported allele frequencies in the NCBI Short Genetic Variation Database (dbSNP) of the ethnicity of our study population (34.1%, EUR population).
Population PK modeling
Plasma PK data were obtained from 118 patients. A population PK model was established utilizing PK data, data from PBMCs, and clinical data obtained prior to and during melphalan treatment to investigate which factors significantly contributed to PK variability among patients. Interpatient variability parameters (IPV) for clearance (CL) and V 2 were strongly associated (r u 0.8), so a shared IPV parameter was used with an estimated scale factor applied to the IPV for V 2 (i.e., IPV V2 5 THETA(n) 3 IPV CL , where THETA(n) is the estimated scale factor).
Covariate adjusted models were developed using a stepwise selection procedure with forward addition and backward elimination. Creatinine clearance (normalized to body surface area of 1.73 m 2 ) and hematocrit on CL, SLC7A5 polymorphism on V 2 , and allometric-scaled fat-free mass were chosen for the final PK model (Supplementary Table 1A,B) . Notably, while backward elimination is often done with a P-value cutoff of 0.01, we chose a cutoff of 0.05, which allowed us to retain hematocrit, which had been reported previously by Nath et al. 13 The inclusion of these four covariates in the final model decreased the overall IPV of CL/V 2 (shared IPV), V 1 , and Q compared to the structural model by 16.9%, 7.8%, and 5.2%, respectively, in which percent difference was calculated by parameter estimates in the structural and final model are listed in Table 3 . The objective function value (OFV) in the final model was reduced by 98.6 compared to the structural model, indicating a significant improvement in the model fitting based on the log likelihood ratio test. Bias and stability of the final model was assessed by 95% CIs of all predicted parameters utilizing the bootstrap method ( Table 4) . The prediction performance of the final model was evaluated by the visual predictive check (VPC) from 1,000 simulation runs, in which the observed melphalan concentration data was compared with the 25 th , 50 th , and 97.5 th percentiles of the predicted values (Figure 1) .
Relationship among PK, PD biomarker, and clinical outcomes
Using pretreatment PBMCs obtained from 118 enrolled patients, we investigated whether PD biomarkers could be a measure of myeloma cell responsiveness to melphalan and explain portions of intersubject variability in outcomes. Following treatment of patients' PBMCs with melphalan, we measured the cytotoxicity (IC 50 ) of melphalan in PBMCs with the WST-1 proliferation assay (n 5 115). The mean ex vivo IC 50 was 21.40 6 15.43 lM (SD), equivalent to 6.53 6 4.71 lg/mL, suggesting high variability in patients' sensitivity to ex vivo melphalan (Supplementary Figure 2) . Interestingly, the log (base 10) transformed ex vivo IC 50 values were marginally associated with mucositis grade (Wilcoxon rank sum test P 5 0.076) (Figure 2) . Melphalan ex vivo potency appeared to be higher in patients with intermediate or severe mucositis (grades 2 and 3) compared to patients with no or mild mucositis (grades 0 and 1) ( Table 5) .
Further, increasing AUC inf and C max was also observed to be associated with worse mucositis grade (median (min-max): AUC inf mgÁhr/L: mucositis grade 0-1: 14.1 (5.6-27.3); mucositis grade 2-3: 16.1 (7.0-26.3); C max mg/mL: mucositis grade 0-1: 8.27 (4.66-12.16); mucositis grade 2-3: 9.70 (5.25-11.60)). Figure 2 and Table 5 describe these associations by mucositis grade. The risk of more severe mucositis (grade 2 or 3) was increased by 21% for every 100 mgÁmin/L, equivalent to 1.67 mgÁhr/L, increase in AUC inf , adjusted for age (age adjusted relative risk for 100 mgÁmin/L increase: 1.21, 95% CI: 1.04, 1.41, P 5 0.015). Similarly, as C max increased so did the risk of more severe mucositis (age adjusted relative risk for 1 mg/mL increase: 1.26, 95% CI: 0.99, 1.60, P 5 0.058). Finally, while both AUC inf and C max were observed to be strongly related to the duration of neutropenia (3.2% increase in duration (95% CI: 2.2%, 5.3%, P 5 0.003) for every 100 mgÁmin/L increase in AUC inf ; 4.8% increase in duration (95% CI: 0.8%, 9.0%, P 5 0.019) for each 1 mg/mL increase in C max , adjusted for age, sex, race, and treatment group), only AUC inf was associated with days hospitalized (0.23 day increase in days hospitalized (95% CI: 0.01, 0.45, P 5 0.043) for every 100 mgÁmin/L increase in AUC inf , adjusted for age, sex, race, and treatment group). Neither AUC inf or C max were strongly associated with time to progression or to overall survival. For our analysis, follow-up for progression and death ended in November 2016, with 53 of 118 patients observed with progression and 28 deaths for median follow-up time of 2.9 years. Adjusted for age, gender, race, and treatment group, the risk of progression decreased marginally as C max increased (adjusted hazard ratio (HR): 0.84, 95% CI: 0.67, 1.05, P 5 0.130). No association was observed between progression and AUC (adjusted HR for 100 mgÁmin/L increase: 0.97, 95% CI: 0.85, 1.10, P 5 0.601). A modest association was observed between overall survival and C max (adjusted for age, race, and gender HR: 0.80, 95% CI: 0.59, 1.08, P 5 0.139) but not with AUC inf (adjusted HR for 100 mgÁmin/L increase: 0.95, 95% CI: 0.81, 1.14, P 5 0.632).
DISCUSSION
The primary purpose of this trial was to investigate whether a shorter duration of cryotherapy was noninferior to the standard 6-h regimen in MM patients. The results from this study indicated that 2 h of cryotherapy was similar (noninferior) to 6 h with respect to grade 3/4 mucositis, length of hospitalization, or development of positive blood cultures; findings that support a 2-h cryotherapy regimen as the new standard of care. 20 As expected, we found a significant association between drug exposure (AUC) and grade of mucositis. This is consistent with results reported in a recent publication by Nath et al., who observed high melphalan AUC is a risk factor for severe mucositis grade. 21 Additionally, serum creatinine and body weight, which were relevant to the final covariates in our PK model, have also been reported as risk factors for the development of oral mucositis. 22 We utilized patient samples and relevant clinical data to establish a PK model based on data from 118 patients. Results from our study were consistent with previously identified covariates of creatinine clearance, fat-free mass, and hematocrit as important factors that explain significant portions of interpatient variability. 13 In our PK model, we observed that fat-free mass explains a significant portion of variability in estimated intercompartmental clearance and central volume among patients, and it enhanced model fitting better (likelihood ratio test, P < 0.001) than other alternative body size descriptors, e.g., body surface area (P < 0.01) or total body weight (P < 0.05). Similarly, several indicators of renal clearance, including calculated creatinine clearance based on serum creatinine using different equations (Cockcroft and Gault or CKD-EPI) and measured creatinine clearance from 24-h urine data, were tested to describe the interpatient variability of melphalan CL. The calculated creatinine clearance using the Cockcroft-Gault equation with total body weight (DOFV 5 -56.49 compared to the base model) was ultimately chosen based on statistical significance and model-fitting results.
Our study also prospectively evaluated for the first time the contribution of a single nucleotide polymorphism (SNP) in SLC7A5 (rs4240803) to melphalan PK, and this revealed a significant effect of SLC7A5 on drug distribution within the peripheral compartment. The SLC7A5 gene is primarily responsible for the uptake of melphalan into cells, 23 and it was identified as a significant variable affecting PK. Drug transporter pharmacogenetics is known to impact drug disposition, 24 and the rs4240803 polymorphism in SLC7A5 had previously been shown to be associated with increased use of TPN following HDM. 18 Until our trial, however, this SLC7A5 polymorphism had not been identified as a predictor of melphalan PK. While a previous study by Kuhne et al. 25 evaluated several polymorphisms in SLC7A5, SLC7A8, and SLC3A2 (the gene encoding the 4F2hc protein, which is the common heavy chain associated protein for both LAT-1 and LAT-2 transporters), this study did not evaluate rs4240803 nor did it identify any significant associations between melphalan pharmacokinetics and any of the polymorphisms evaluated within the 64 patients enrolled. The rs4240803 polymorphism is in the first intron of SLC7A5, and its function is not currently known. Giglia et al. 18 point out that this intron is within a region near a putative transcriptional enhancer, and it could therefore impact mRNA expression levels. 26 Our observations suggest SLC7A5 may influence melphalan distribution within peripheral compartments, which is consistent with other findings for drug transporter pharmacogenetics. 27 Incorporating this covariate into our PK model further enhanced the ability of the model to predict melphalan plasma concentrations.
Fat-free mass, creatinine clearance, and hematocrit explain 17.5% of interpatient variability of melphalan CL compared to the structural PK model (unexplained interpatient variability decreased from 33.8% to 27.9%), which is nearly identical to the findings previously published by Nath et al. in a 100-patient dataset (33.6% to 26.7%). 13 Overall, results from our study serve as a validation for the previously published model. 13 While we discovered that inclusion of SLC7A5 as a covariate on V 2 did further improve the model fitting, interpatient variability was not decreased by addition of this covariate. Furthermore, with data from 118 patients, we observed good model stability and precision with narrow 95% CIs of bootstrap iterations compared to the parameter estimates from the final model (Table 4 ). In the VPC results, plasma concentrations were slightly overpredicted at early timepoints, presumably due to underpredicted drug distribution caused by sparse data, extended infusion time (28-59 min), or highly variable protein-binding fraction of melphalan in some patients (Figure 1) . Based on the previous study and the data presented herein, this PK model will be a useful tool for predicting patients' melphalan PK and melphalan exposure-related outcomes, although more work will need to be done to better predict melphalan concentrations at the early timepoints. The relationship observed between ex vivo IC 50 and mucositis suggests that IC 50 may be a potential biomarker for melphalan toxicities. Induction of apoptosis upon ex vivo melphalan exposure in PBMCs from MM patients was previously correlated with their in vivo response to melphalan treatment.
14 This suggests that ex vivo IC 50 might be a useful indicator for the sensitivity level of plasma cells in MM patients to melphalan exposure. In this respect, while the PK results are important for clinicians to consider, melphalan-induced cell death is critical to understanding variability in outcomes from melphalan therapy. These results suggest more specific PD biomarkers may enable us to further improve the melphalan dosing regimen.
The recent study by Nath et al. 21 demonstrated that higher melphalan exposure is associated with more severe grade of mucositis, although higher exposure was also associated with longer overall survival. Pharmacokinetic results from our study (AUC range 5.6-27.3 mgÁhr/L, median 14.4 mgÁhr/L) were similar to those reported in the Nath study (4.9-24.6 mgÁhr/L, median 12.8 mgÁhr/L). Time to progression and overall survival are modestly associated with C max in our study. The observation that increased melphalan AUC may lead to improved progression-free and overall survival in the Nath study highlights a potential advantage to being able to predict melphalan PK and exposure in individual patients. However, it is still not clear how this information can be used to optimize dosing to achieve maximum efficacy (i.e., prolong progression-free and overall survival) while maintaining a reasonable margin of safety. Mucositis can be a severe and painful toxicity, but other melphalan-induced toxicities, such as prolonged severe neutropenia, can be lifethreatening. To highlight this point, Nath et al. indicated "Eighty-two percent of patients experienced febrile neutropenia. One patient, with a melphalan AUC of 18.4 mg l -1 h, died due to bacterial pneumonia on day 100 post-transplant. . .." 21 In our study, the duration of severe neutropenia (ANC <500 cells per mL) ranged from 2.9 to 13.2 days with a median of 5.7 days. As the risk of infection increases with the duration of severe neutropenia, one strategy for dose optimization may be to maximize melphalan AUC while minimizing the duration of severe neutropenia. As melphalan exposure was associated with duration of severe neutropenia in our study, we are currently pursuing such a strategy.
The primary aim of this study was to compare the effectiveness of 2-h vs. 6-h cryotherapy with respect to mucositis and patient tolerance of HDM. The results indicated that 2 h of cryotherapy was at least as effective at reducing severe oral mucositis as 6 h. Correlative analyses, including the development of a population PK model and identification of significant covariates that explain interpatient variability, have provided us tools for predicting melphalan exposure prior to treatment via analysis of relevant patient factors including creatinine clearance, fat-free mass, hematocrit, and SLC7A5 rs4240803 genotype. Further work to improve and link this model to outcomes from therapy is underway for personalizing melphalan dosing to minimize adverse outcomes without sacrificing efficacy from HSCT therapy in MM patients.
METHODS

Clinical study design
This single-institution, randomized, controlled noninferiority trial was approved by The Ohio State University Cancer Institutional Review Board, and written informed consent was obtained from all enrolled patients (NCT01653106). Adult patients with multiple myeloma as defined by the International Myeloma Working Group (IWMG) diagnostic criteria admitted for autologous stem cell transplantation were eligible for enrollment. 28 Patients were enrolled and randomized in equal numbers to receive either 2 or 6 h of cryotherapy, with the randomization scheme blocked and stratified by: hemoglobin (<11 g/dL or !11 g/ dL), fat-free mass (30-50 kg, 50-70 kg, or > 70 kg), and measured creatinine clearance (<30 mL/min, 30-60 mL/min, or >60 mL/min).
We hypothesized that 2 h of cryotherapy would be noninferior to 6 h of cryotherapy with a noninferiority margin of 15% with respect to the rate of severe (grade 3 or worse) mucositis. Previous work had observed that $15% of patients on 3 h of cryotherapy developed grade 3/4 mucositis. Our null hypothesis was that if the true severe mucositis rate for 6 h of cryotherapy is 15%, then the corresponding true severe mucositis rate for 2 h of cryotherapy is 30% or greater. With a sample size of 146 evaluable patients (73 per arm), we would have at least 80% power for a one-sided test of these hypotheses with a significance level of 0.05.
The primary study endpoint of noninferiority in severe mucositis and related secondary endpoints (any mucositis and grade 2 or worse mucositis) was evaluated through the difference and associated 90% CIs in these rates between randomized treatment groups (all patients received therapy as assigned). Noninferiority was considered to be established if the upper limit of the 90% CI was below the noninferiority margin of 15%, based on a large sample difference in proportions confidence interval. Differences between treatment groups in the incidence of bacteremia were estimated by the two-sample test of proportions and by a two-sample t-test for length of hospital stay, at the two-sided 5% level. Associations between mucositis grade and bacteremia or length of hospital stay were estimated through logistic or linear regression models, adjusted for age and treatment group. All reported P-values and CIS were two-sided and reported at the nominal level unadjusted for multiple comparisons; all analyses were performed using Stata 13.0 (StataCorp, College Station, TX). 29 Treatment. Cryotherapy was initiated 15 min prior to the start of the melphalan infusion and continued for either 2 or 6 h depending on treatment arm. Over the duration of the cryotherapy regimen, bone marrow transplant-specific nursing staff documented patient adherence and total number of cups of ice consumed. Patients refrained from other oral intake during cryotherapy and were instructed to melt $1 ounce of shaved ice (flavoring permitted) in their mouth with immediate replenishment. A single dose of melphalan was infused over 30 min on day -2 (2 days prior to transplant) in all patients and included 200 mg/m 2 except those patients !75 years, body mass index (BMI) <19, and/or with significant renal or cardiac dysfunction, who were treated with 140 mg/m 2 . All patients received 12 mg dexamethasone on day -2, 8 mg on day -1, and 8 mg either once or twice daily on days 0 and 11. Stem cell support with granulocyte colony-stimulating factor (G-CSF) was started either on day 11 or 17 based on the institutional standard of care protocol at the time. Patients were followed for adverse events and patient reported outcomes.
Safety and tolerability assessments
Baseline demographics were obtained at the time of enrollment and included age, race, gender, height, weight, measured creatinine clearance, hemogram, myeloma disease status, albumin, total bilirubin, total serum protein, and c-reactive protein. Other data were collected daily and included presence or absence of bacteremia and/or neutropenic fever, TPN use, and diarrhea. Patients were assessed for oral mucositis per the World Health Organization (WHO) criteria (Supplementary Table 2 ).
Blood sample collection and pharmacokinetic studies Blood samples were collected from 119 patients enrolled for PK analysis. Similar to a sampling scheme recommended previously for melphalan, 13 venous blood samples were collected in heparin tubes prior to melphalan administration and then 5, 30, 45, 60, 180, and 360 min after completion of melphalan infusion (a subset of patients also had samples collected at the end of the infusion and at 15 min after infusion). Blood sample analyses and PK modeling methods are described in the Supplementary Methods.
PBMC collection for PD biomarker studies
Approximately 24 mL samples of venous blood were obtained in green top (heparin) tubes within 2 h prior to the infusion of melphalan. Samples were collected, mixed, placed on ice, and transported to The Ohio State University Leukemia Tissue Bank where Ficoll-Hypaque was used to isolate PBMCs prior to storage at -708C. While every attempt was made to obtain PBMCs from all patients who provided plasma PK samples, adequate quantities of viable PBMCs to conduct ex vivo and genotyping studies, as described below, were available from only a subset of the patients. PD biomarker experiments are described in the Supplementary Methods.
Relationship among PK, PD biomarker, and clinical outcomes The relationship between ex vivo IC 50 , AUC inf , and C max values with worst mucositis grade (0 & 1 vs. 2 & 3) was initially assessed by twosided Wilcoxon rank sum tests with continuity correlation (R, v. 3.1.1, Vienna, Austria). The adjusted (for age, race, gender, and treatment group) relative risk of worse mucositis grade and IC 50 , AUC inf , and C max was made via modified Poisson regression. 30 The ex vivo IC 50 values of PBMCs were subjected to log (base 10) transformation prior to statistical analyses. Associations between each PK, PD marker, and duration of neutropenia or hospital stay was assessed via linear regression, with duration of neutropenia natural log transformed to account for the strong skewness in distribution. The risk of progression or the risk of death associated with level of AUC inf or C max was made via Cox proportional hazards models, with baseline hazard stratification on age group. The time to progression was measured as the time from transplant until the date of progression, or progression time was censored on the date a patient was last known to be progression-free. Overall survival was calculated as the time from transplant to death or the date last known to be alive.
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